v3.24.4
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Cash Flows from Operating Activities        
Net loss $ (5,302,205) $ (5,545,795) $ (14,550,609) $ (6,924,965)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation 85,590 78,121 105,674 26,888
Stock based compensation 1,240,982 1,212,279 1,577,440 1,644,269
Amortization of intangible assets 571,347 571,347 761,796 776,793
Amortization of product development costs 221,207 53,771 15,029
Amortization of software development costs 248,203 23,354
Loss on disposal of fixed assets 1,654    
Goodwill impairment     7,815,000
Deferred taxes (benefit) expense     (320,102) 124,468
Changes in operating assets and liabilities:        
Accounts receivable (102,886) 390,401 388,948 (303,846)
Inventory 358,739 609,425 567,755 (507,931)
Prepaid expenses and other current assets (26,313) (331,776) (111,080) 500,093
Accounts payable (644,091) (83,040) 22,193 180,621
Accrued expenses (63,802) (492,455) (649,620) 859,294
Deferred revenue 150,007    
Net Cash Used in Operating Activities (3,261,568) (3,591,493) (4,315,480) (3,609,287)
Cash flows from Investing Activities        
Purchase of equipment and website development (23,201) (51,073) (53,429) (282,466)
Product development costs (339,402) (400,895) (562,610) (661,673)
Software development costs (686,761) (583,561) (757,396) (364,018)
Net Cash Used in Investing Activities (1,049,364) (1,035,529) (1,373,435) (1,308,157)
Cash flows from Financing Activities        
Proceeds from the sale of common stock and warrants 4,492,198 5,211,428 5,211,428
Fees paid in connection with equity offerings (772,580) (816,017) (1,026,607)
Common stock withheld to pay taxes (4,235)    
Proceeds from exercise of warrants for common stock 8,220 162,494 1,165,156
Series C redeemable preferred stock dividends (225,000) (225,000) (300,000) (300,000)
Net Cash Provided by Financing Activities 3,498,603 4,332,905 5,049,977 (300,000)
Net Decrease in Cash, Cash Equivalents and Restricted Cash (812,329) (294,117) (638,938) (5,217,444)
Cash, Cash Equivalents and Restricted Cash - Beginning of Period 6,398,164 7,037,102 7,037,102 12,254,546
Cash, Cash Equivalents and Restricted Cash - End of Period 5,585,835 6,742,985 6,398,164 7,037,102
Cash paid during the years for:        
Taxes     3,152
Non-cash investing and financing activities:        
Accrued preferred stock dividends     48,389
Conversion of Series F preferred stock to common stock 201,000 201,000
Common stock issued to settle Series F preferred stock dividends 48,389 48,389
Fees in connection with offering costs included in accounts payable and accrued expenses 188,120    
Product development costs included in accounts payable and accrued expenses 104,243 69,595 113,538
Software development costs included in accounts payable and accrued expenses $ 89,379 $ 71,231 201,841
Website development included in accounts payable     $ 18,494